EichorEICHOR
Location: Fuzhou Synced from ClinicalTrials.gov · August 07, 2026

Clinical studies recruiting near Fuzhou

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Hav
Phase 3 · Fujian Medical University Union Hospital · Pfizer · NCT05020236
Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUre
Phase 3 · Fujian Provincial Hospital · Tasly Pharmaceutical Group Co., Ltd · NCT07687186
Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer
Phase 1/Phase 2 · Department of Nuclear Medicine, First Affiliated Hospital of · First Affiliated Hospital of Fujian Medical University · NCT07363486
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
Phase 1/Phase 2 · Fujian provincial cancer hospital · Sichuan Enray Pharmaceutical Sciences Company · NCT07433283
A Registered Cohort Study on Charcot-Marie-Tooth Disease
Phase N/A · First Affiliated Hospital of Fujian Medical University · Ning Wang, MD., PhD. · NCT04010188
Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorec
Phase 2 · Fujian Cancer Hospital · Fudan University · NCT06521866
Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
Phase 3 · Fujian Medical University Union Hospital · Eye & ENT Hospital of Fudan University · NCT06235203
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease
Phase 2/Phase 3 · Local Institution - 0048 · Bristol-Myers Squibb · NCT07106762
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in
Phase 3 · Fujian Cancer Hospital · Pfizer · NCT06758401
Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Mod
Phase 3 · Fujian Medical University Union Hospital · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT06682169
A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With
Phase 2 · Mengchao Hepatobiliary Hospital, Fujian Medical University · Meng Chao Hepatobiliary Hospital of Fujian Medical Universit · NCT06280105
A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves T
Phase 1 · Mengchao Hepatobiliary Hospital of Fujian Medical University · AbbVie · NCT06487559
PulseSelect™ PFA Global Registry
Phase N/A · Fujian Provincial Hospital · Medtronic Cardiac Ablation Solutions · NCT06393920
Validation of CAGIB Score for In-hospital Mortality of Cirrhotic Patients With Acute Gastrointestinal Bleeding
Phase N/A · First Affiliated Hospital of Fujian Medical University · Xingshun Qi · NCT04662918
Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC
Phase 2 · Fujian Medical University Union Hospital · Guangdong Association of Clinical Trials · NCT05536505
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
Phase 1/Phase 2 · Fujian Provincial Cancer Hospital · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharm · NCT06431490
Artificial Intelligence-driven Virtual Standardized Pediatric Patients Trial
NA · Jinxi County People's Hospital · Southern Medical University, China · NCT06699433
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multi
Phase 1 · Fujian Cancer Hospital · Shanghai Henlius Biotech · NCT07160335
The Impact of Transjugular Intrahepatic Portosystemic Shunt on Recompensation in Patients With Decompensated Liver Cirrh
Phase N/A · Fujian Medical University Union Hospital · Union Hospital, Tongji Medical College, Huazhong University · NCT07172035
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants Wit
Phase 1/Phase 2 · Local Institution - 0116 · Bristol-Myers Squibb · NCT07291076
Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Brea
Phase 2/Phase 3 · Fujian Cancer Hospital · Shanghai Pharmaceuticals Holding Co., Ltd · NCT05744687
Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (
Phase 3 · Fujian Medical University Union Hospital · Fudan University · NCT05909332
Tumor Regression Grade As Predictor of Adjuvant Therapy
Phase N/A · Fujian Medical University Union Hospital · Fujian Medical University Union Hospital · NCT06710665
A Study of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors
Phase 1 · Fujian Cancer Hospital · Heronova Pharmaceuticals · NCT07071090
68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI
Phase 2/Phase 3 · Department of Nuclear Medicine, First Affiliated Hospital of · First Affiliated Hospital of Fujian Medical University · NCT07209878
Postoperative Radiotherapy for Early-stage Oral Tongue Squamous Cell Carcinoma Patients With Risk Factors: a Prospective
NA · Fujian Cancer Hospital · Second Affiliated Hospital, Zhejiang University, School of M · NCT07402525
RATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC
Phase N/A · Fujian Medical University Union Hospital · Shanghai Chest Hospital · NCT07541521
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangement
Phase 1/Phase 2 · Local Institution - 6719 · Turning Point Therapeutics, Inc. · NCT03093116
IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer
Phase 1/Phase 2 · Fujian Cancer Hospital · InxMed (Shanghai) Co., Ltd. · NCT05551507
A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.
Phase 1/Phase 2 · Fujian Cancer Hospital · Advenchen Laboratories, LLC · NCT07392736
Look up another city
Look up another condition